Showing 1 - 7 results of 7 for search 'Tünde Tarr', query time: 0.03s Refine Results
  1. 1
    Changes in Clinical Manifestations and Course of Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome over Three Decades

    Changes in Clinical Manifestations and Course of Systemic Lupus Erythematosus and Secondary Antiphospholipid Syndrome over Three Decades by Nikolett Nagy, Gábor Papp, Eszter Gáspár-Kiss, Ágnes Diószegi, Tünde Tarr

    Published 2023-04-01
    Get full text
    Article
  2. 2
    P93 Investigation of clinical and laboratory characteristics and survival of SLE patients with and without lupus nephritis

    P93 Investigation of clinical and laboratory characteristics and survival of SLE patients with and without lupus nephritis by Tunde Tarr, Bianka Perge, Bernadett Bói, Eszter Gáspár-Kiss, Gábor Papp

    Published 2024-03-01
    Article
  3. 3
    Fatal CMV-Infection after Autologous Stem Cell Transplantation in Refractory Systemic Lupus Erythematosus

    Fatal CMV-Infection after Autologous Stem Cell Transplantation in Refractory Systemic Lupus Erythematosus by László Váróczy, Emese Kiss, Tünde Tarr, Margit Zeher, Gyula Szegedi, Árpád Illés

    Published 2012-01-01
    Get full text
    Article
  4. 4
    Clinical Features and Survival Analysis of Lupus Nephritis among Patients with Systemic Lupus Erythematosus: A Three-Decade-Long Retrospective Cohort Study

    Clinical Features and Survival Analysis of Lupus Nephritis among Patients with Systemic Lupus Erythematosus: A Three-Decade-Long Retrospective Cohort Study by Bianka Perge, Gábor Papp, Bernadett Bói, Nikolett Nagy, Eszter Gáspár-Kiss, Tünde Tarr

    Published 2024-09-01
    Get full text
    Article
  5. 5
    Role of Altered Metabolism of Triglyceride-Rich Lipoprotein Particles in the Development of Vascular Dysfunction in Systemic Lupus Erythematosus

    Role of Altered Metabolism of Triglyceride-Rich Lipoprotein Particles in the Development of Vascular Dysfunction in Systemic Lupus Erythematosus by Ágnes Diószegi, Hajnalka Lőrincz, Eszter Kaáli, Pál Soltész, Bianka Perge, Éva Varga, Mariann Harangi, Tünde Tarr

    Published 2023-02-01
    Get full text
    Article
  6. 6
    Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus

    Antiphospholipid Antibodies Are Major Risk Factors for Non-Thrombotic Cardiac Complications in Systemic Lupus Erythematosus by Nikolett Nagy, Bernadett Bói, Gábor Papp, Edit Fiák, Eszter Gáspár-Kiss, Bianka Perge, Nikolett Farmasi, Tünde Tarr

    Published 2024-02-01
    Get full text
    Article
  7. 7
    LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus (SLE)

    LO-021 Interim safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; anti-BAFF-R mAb) administered monthly over 28 weeks in patients with systemic lupus erythematosus... by Yuko Kaneko, Masato Okada, Stephanie Finzel, Nan Shen, Elena Vishneva, Lingyun Sun, Bernadette Rojkovich, Alberta Hoi, Shin-Seok Lee, Piotr Leszczyński, Lie Dai, Rafal Wojciechowski, Cheng-Chung Wei, Katarzyna Romanowska-Prochnicka, Hiroshi Kaneko, Stanislav Ignatenko, Alexander Gordienko, Josefina Hernandez, Nancy Levin, Pongthorn Narongroeknawin, Hanna Ciferska, Masanari Kodera, Joung Liang Lan, Tunde Tarr, Yi Hsing Chen, Ajchara Koolvisoot, Eugeny Zotkin, Berta Paula magallares, Tirtha Sengupta, Carole Sips, Stephan Oliver

    Published 2023-07-01
    Article

Search Tools: